Evaluating Novel Target Trial Data, Isotope Selection, Dosimetry Assessment, & Share Regulatory Insights to Drive & Achieve RLT Potential as First-Line & Combination Therapies in Modern Oncology.
Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pipelines are rapidly expanding beyond lutetium into next-generation alpha emitters and novel targets, and developers are racing to bring transformative radioligand therapies to patients. As the field matures, the industry’s greatest challenges involve clinical translation, isotope availability, manufacturing scale-up and regulatory alignment.
The 8th Targeted Radiopharmaceuticals Summit Europe unites the scientific, clinical, manufacturing, regulatory and commercial leaders driving this transformation to build the blueprint for Europe’s next generation of targeted radiopharmaceuticals.
View Event
